Results 91 to 100 of about 28,540 (254)

Distribution and Redistribution of HIV-1 Nucleocapsid Protein in Immature, Mature, and Integrase-Inhibited Virions: a Role for Integrase in Maturation [PDF]

, 2015
During virion maturation, HIV-1 capsid protein assembles into a conical core containing the viral ribonucleoprotein (vRNP) complex, thought to be composed mainly of the viral RNA and nucleocapsid protein (NC).
Cheng, N, Engelman, AN, Fontana, J, Fuchs, JR, Gorelick, RJ, Jurado, KA, Ly, NL, Steven, AC   +7 more
core   +1 more source

Feline leukaemia virus (FeLV) infection in domestic pet cats in Australia and New Zealand: Guidelines for diagnosis, prevention and management

Australian Veterinary Journal, EarlyView.
Progressive feline leukaemia virus (FeLV) infection dramatically shortens the lives of infected cats, causing acquired immunodeficiency, aplastic anaemia, lymphoma, leukaemia and other myeloproliferative diseases. The potential impact of regressive FeLV infection on the development of disease remains largely unknown, although there is evidence it ...
ME Westman, SJ Coggins, M van Dorsselaer, JM Norris, RA Squires, M Thompson, R Malik   +6 more
wiley   +1 more source

HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.

PLoS ONE, 2014
To characterize the HIV-2 integrase gene polymorphisms and the pathways to resistance of HIV-2 patients failing a raltegravir-containing regimen, we studied 63 integrase strand transfer inhibitors (INSTI)-naïve patients, and 10 heavily pretreated ...
Joana Cavaco-Silva, Ana Abecasis, Ana Cláudia Miranda, José Poças, Jorge Narciso, Maria João Águas, Fernando Maltez, Isabel Almeida, Isabel Germano, António Diniz, Maria de Fátima Gonçalves, Perpétua Gomes, Celso Cunha, Ricardo Jorge Camacho, Portuguese HIV-2 Resistance Study Group   +14 more
doaj   +1 more source

A Fluorescent Assay to Search for Inhibitors of HIV-1 Integrase Interactions with Human Ku70 Protein, and Its Application for Characterization of Oligonucleotide Inhibitors

Biomolecules, 2020
The search for compounds that can inhibit the interaction of certain viral proteins with their cellular partners is a promising trend in the development of antiviral drugs.
Simon Galkin, Anna Rozina, Arthur Zalevsky, Marina Gottikh, Andrey Anisenko   +4 more
doaj   +1 more source

Non-AIDS-related comorbidities in people living with HIV-1 aged 50 years and older: The AGING POSITIVE study. [PDF]

, 2018
OBJECTIVE: To characterize the profile of non-AIDS-related comorbidities (NARC) in the older HIV-1-infected population and to explore the factors associated with multiple NARC.
Abreu, R, Almeida, J, Castro, R, Coutinho, D, Lino, S, Lopes, MJ, Maltez, F, Mansinho, K, Miranda, AC, Neves, I, Pacheco, P, Piñero, C, Pássaro, L, Sarmento, E, Serrão, R, Tavares, AP, Velez, J   +16 more
core   +1 more source

Organoid Models to Study Human Infectious Diseases

Cell Proliferation, EarlyView.
Our manuscript reviews the role of organoids as models for studying human infectious diseases, highlighting their irreplaceable contributions to drug testing and vaccine development for significant infectious diseases including HIV, ZIKV, SARS‐CoV‐2 and MPXV.
Sijing Zhu, Dan Chen, Xinzhi Yang, Liuliu Yang, Yuling Han   +4 more
wiley   +1 more source

Targeting STAT3 in Cancer with Nucleotide Therapeutics. [PDF]

, 2019
Signal transducer and activator of transcription 3 (STAT3) plays a critical role in promoting the proliferation and survival of tumor cells. As a ubiquitously-expressed transcription factor, STAT3 has commonly been considered an "undruggable" target for ...
Grandis, Jennifer R, Johnson, Daniel E, Lau, Yue-Ting K, Ramaiyer, Malini   +3 more
core   +2 more sources

Patient‐reported outcomes in clinical trials assessing the effectiveness of cabotegravir + rilpivirine long‐acting injections as antiretroviral therapy: A systematic review

HIV Medicine, EarlyView.
Abstract Introduction: Human immunodeficiency virus‐1 (HIV‐1) continues to have a high global burden, with approximately 39.9 million people currently living with the virus. Despite the clinical success of antiretroviral therapy (ART), adherence remains a significant challenge, often due to emotional distress and HIV‐related stigma.
Dhruv Vinay, Iresh Jayaweera, Meghan Bowman, Don Thiwanka D Wijeratne   +3 more
wiley   +1 more source

Maraviroc (Celsentri) in HIV treatment

Farmeconomia: Health Economics and Therapeutic Pathways, 2008
Since 1996, the prognosis of people living with immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) has improved significantly, due to highly active antiretroviral therapies (HAART) based on a combination of 3-4 anti-HIV drugs; the
Viola Sacchi
doaj   +1 more source

Rapid start with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment in people with human immunodeficiency virus‐1 (HIV‐1): A systematic literature review of clinical and patient‐reported outcomes

HIV Medicine, EarlyView.
Abstract Background Treatment guidelines recommend rapid antiretroviral therapy (ART) initiation among eligible people with HIV to improve treatment outcomes and reduce HIV transmission. Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), an integrase strand transfer inhibitor‐based single‐tablet regimen, is recommended for rapid start in US and
Jade Ghosn, Jeremy Chow, Monica Gandhi, Miguel Górgolas, Aws Al‐Hayani, Hansel Tookes, Max Lee, Emily F. Kaiser, David Malebranche, Fernando Alvarez Bognar, Bhumi Gandhi‐Patel, Lili Dai   +11 more
wiley   +1 more source